Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

A. S. Kubasch; P. Peterlin; T. Cluzeau; K. S. Götze; K. Sockel; R. Teipel; M. Jentzsch; H. Attalah; M. Sebert; F. Chermat; S. Gloaguen; M. Puttrich; M. Cross; M. Schneider; S. Kayser; D. Schipp; A. Giagounidis; I. Tirado-Gonzalez; A. Descot; A. van de Loosdrecht; A. Weigert; K. H. Metzeler; P. Fenaux; H. Medyouf; U. Platzbecker; L. Ades

doi:10.1038/s41375-023-02029-1

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

A. S. Kubasch, P. Peterlin, T. Cluzeau, K. S. Götze, K. Sockel, R. Teipel, M. Jentzsch, H. Attalah, M. Sebert, F. Chermat, S. Gloaguen, M. Puttrich, M. Cross, M. Schneider, S. Kayser, D. Schipp, A. Giagounidis, I. Tirado-Gonzalez, A. Descot, A. van de LoosdrechtA. Weigert, K. H. Metzeler, P. Fenaux, H. Medyouf, U. Platzbecker, L. Ades

Department of Internal Medicine III - Hematology and Medical Oncology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Original language	English
Pages (from-to)	2309-2313
Number of pages	5
Journal	Leukemia
Volume	37
Issue number	11
DOIs	https://doi.org/10.1038/s41375-023-02029-1
State	Published - Nov 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41375-023-02029-1

Cite this

Kubasch, A. S., Peterlin, P., Cluzeau, T., Götze, K. S., Sockel, K., Teipel, R., Jentzsch, M., Attalah, H., Sebert, M., Chermat, F., Gloaguen, S., Puttrich, M., Cross, M., Schneider, M., Kayser, S., Schipp, D., Giagounidis, A., Tirado-Gonzalez, I., Descot, A., ... Ades, L. (2023). Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial. Leukemia, 37(11), 2309-2313. https://doi.org/10.1038/s41375-023-02029-1

@article{87ccf46202d24f4eb2d1d23e115452f0,

title = "Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial",

author = "Kubasch, {A. S.} and P. Peterlin and T. Cluzeau and G{\"o}tze, {K. S.} and K. Sockel and R. Teipel and M. Jentzsch and H. Attalah and M. Sebert and F. Chermat and S. Gloaguen and M. Puttrich and M. Cross and M. Schneider and S. Kayser and D. Schipp and A. Giagounidis and I. Tirado-Gonzalez and A. Descot and {van de Loosdrecht}, A. and A. Weigert and Metzeler, {K. H.} and P. Fenaux and H. Medyouf and U. Platzbecker and L. Ades",

note = "Funding Information: The BERGAMO study was partially supported by BerGenBio. Open Access funding enabled and organized by Projekt DEAL. ",

year = "2023",

month = nov,

doi = "10.1038/s41375-023-02029-1",

language = "English",

volume = "37",

pages = "2309--2313",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "11",

}

Kubasch, AS, Peterlin, P, Cluzeau, T, Götze, KS, Sockel, K, Teipel, R, Jentzsch, M, Attalah, H, Sebert, M, Chermat, F, Gloaguen, S, Puttrich, M, Cross, M, Schneider, M, Kayser, S, Schipp, D, Giagounidis, A, Tirado-Gonzalez, I, Descot, A, van de Loosdrecht, A, Weigert, A, Metzeler, KH, Fenaux, P, Medyouf, H, Platzbecker, U & Ades, L 2023, 'Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial', Leukemia, vol. 37, no. 11, pp. 2309-2313. https://doi.org/10.1038/s41375-023-02029-1

TY - JOUR

T1 - Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

AU - Kubasch, A. S.

AU - Peterlin, P.

AU - Cluzeau, T.

AU - Götze, K. S.

AU - Sockel, K.

AU - Teipel, R.

AU - Jentzsch, M.

AU - Attalah, H.

AU - Sebert, M.

AU - Chermat, F.

AU - Gloaguen, S.

AU - Puttrich, M.

AU - Cross, M.

AU - Schneider, M.

AU - Kayser, S.

AU - Schipp, D.

AU - Giagounidis, A.

AU - Tirado-Gonzalez, I.

AU - Descot, A.

AU - van de Loosdrecht, A.

AU - Weigert, A.

AU - Metzeler, K. H.

AU - Fenaux, P.

AU - Medyouf, H.

AU - Platzbecker, U.

AU - Ades, L.

N1 - Funding Information: The BERGAMO study was partially supported by BerGenBio. Open Access funding enabled and organized by Projekt DEAL.

PY - 2023/11

Y1 - 2023/11

UR - http://www.scopus.com/inward/record.url?scp=85171658935&partnerID=8YFLogxK

U2 - 10.1038/s41375-023-02029-1

DO - 10.1038/s41375-023-02029-1

M3 - Article

AN - SCOPUS:85171658935

SN - 0887-6924

VL - 37

SP - 2309

EP - 2313

JO - Leukemia

JF - Leukemia

IS - 11

ER -

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

UN SDGs

Access to Document

Other files and links

Cite this